Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002543882 | SCV003240912 | likely benign | Rubinstein-Taybi syndrome due to EP300 haploinsufficiency | 2023-02-14 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003355525 | SCV004070452 | likely benign | Inborn genetic diseases | 2023-07-20 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
O&I group, |
RCV001849226 | SCV001960871 | uncertain significance | Autosomal dominant cerebellar ataxia | 2021-07-22 | no assertion criteria provided | research | |
Prevention |
RCV003968520 | SCV004779752 | uncertain significance | EP300-related disorder | 2024-02-23 | no assertion criteria provided | clinical testing | The EP300 c.214C>A variant is predicted to result in the amino acid substitution p.Gln72Lys. This variant has been reported as a variant of uncertain significance in a cohort study of spinocerebellar ataxia (Ghorbani et al. 2022. PubMed ID: 35401678). This variant is reported in 0.0070% of alleles in individuals of European (Non-Finnish) descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |